| Literature DB >> 22363418 |
William R Wright1, Katarzyna Parzych, Damian Crawford, Charles Mein, Jane A Mitchell, Mark J Paul-Clark.
Abstract
BACKGROUND: Cigarette smoking is responsible for 5 million deaths worldwide each year, and is a major risk factor for cardiovascular and lung diseases. Cigarette smoke contains a complex mixture of over 4000 chemicals containing 10(15) free radicals. Studies show smoke is perceived by cells as an inflammatory and xenobiotic stimulus, which activates an immune response. The specific cellular mechanisms driving cigarette smoke-induced inflammation and disease are not fully understood, although the innate immune system is involved in the pathology of smoking related diseases. METHODOLOGY/PRINCIPLEEntities:
Mesh:
Substances:
Year: 2012 PMID: 22363418 PMCID: PMC3281820 DOI: 10.1371/journal.pone.0030120
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1THP-1 samples treated for 8 h with control media or 10% CSE group according to treatment conditions.
THP-1 cells were treated for 8 h with control media or 10% CSE, RNA was extracted and gene expression values measured using HumanRef-8v3 Expression BeadChip arrays. Principal component analysis (PCA) by conditions was performed on GeneSpring GX 11.0.2 and represented as a 3D scatterplot of THP-1 monocytes treated with control media or 10% cigarette smoke extract (CSE) for 8 hours from 6 individual experiments.. The PCA plot showed that samples clustered based on their treatment with medium (blue) or 10% CSE (red). Data represent n = 6. Component % variance; PC1 = 81.7%, PC2 = 14.1%, PC3 = 4.2%. RNA was extracted from each sample and gene expression values measured using 2 HumanRef-8v3 Expression BeadChip arrays. This represents stratification according to treatment with 10% CSE (red) and media treated controls (blue) over 6 individual experiments.
Figure 2Expression of genes that were increased above a 1.5-fold cut-off in THP-1 monocytes treated with control medium or cigarette smoke extract (CSE) for 8 hours.
THP-1 monocytes were treated for 8 hours with RPMI-1640 medium (control 1–6) or CSE (1–6). RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representation of normalized signal intensity values for genes altered by ≥1.5-fold. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. (B) Table showing gene symbol, fold change and p-value for all genes upregulated by ≥1.5-fold. Statistical significance (p<0.05) was calculated using student's t-test followed by Benjamini-Hochberg false discovery rate correction on GeneSpring GX11.0.2 software. Fold change represents a comparison between mean normalised signal intensity for control (n = 6) versus smoke (n = 6) treated THP-1 monocytes. Refer to Data S1 for full data sets and Entrez Gene IDs.
Figure 3Expression of genes that were decreased below a 1.5-fold cut-off in THP-1 monocytes treated with control medium or cigarette smoke extract for 8 hours.
THP-1 monocytes were treated for 8 hours with RPMI-1640 medium (control 1–6) or CSE (1–6). RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representation of normalized signal intensity values for genes altered by ≥1.5-fold. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. (B) Table showing gene symbol, fold change and p-value for all genes downregulated by ≥1.5-fold. Statistical significance (p<0.05) was calculated using student's t-test followed by Benjamini-Hochberg false discovery rate correction on GeneSpring GX11.0.2 software. Fold change represents a comparison between mean normalised signal intensity for control (n = 6) versus smoke (n = 6) treated THP-1 monocytes. Refer to Data S1 for full data sets and Entrez Gene IDs.
Figure 4Expression of genes that were changed by 2.0-fold or above in THP-1 monocytes treated with control medium or cigarette smoke extract for 8 hours.
THP-1 monocytes were treated for 8 hours with RPMI-1640 medium (control 1–6) or CSE (1–6). RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representation of normalized signal intensity values for genes altered by ≥2.0-fold. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. (B) Table showing gene name, fold change and p-value for all genes upregulated by ≥2.0-fold. (C) Table showing gene name, fold change and p-value for all genes downregulated by ≥2.0-fold. Statistical significance (p<0.05) was calculated using student's t-test followed by Benjamini-Hochberg FDR correction on GeneSpring GX11.0.2 software. Fold change represents a comparison between mean normalised signal intensity for control (n = 6) versus smoke (n = 6) treated THP-1 monocytes. Refer to Data S1 full data sets and Entrez Gene IDs.
Figure 53D Scatterplot from the principle conponent analysis of PBMCs treated with control media or cigarette smoke extract (CSE) for 8 and 24 hours.
PBMCs were treated with control media, 3% CSE or 10% CSE for 8 and 24 hours. RNA was extracted from each sample and gene expression values measured using HumanRef-8v3 Expression BeadChip arrays. Samples stratify according to treatment with 3% CSE (maroon), 10% CSE (red) and media treated controls (blue) from 3 individuals for (A) 8 hours and (B) 24 hours. Component % variance for 8 hours was; PC1 = 35.8%, PC2 = 27.6%, PC3 = 19.2%, PC4 = 17.4%. Component % variance for 24 hours was; PC1 = 44.1%, PC2 = 22.4%, PC3 = 18.8%, PC4 = 14.7%.
Figure 6Expression of genes that were changed by 3.0-fold or above in PBMCs treated with control medium or cigarette smoke extract (CSE) for 8 hours.
PBMCs were treated for 8 hours with RPMI-1640 medium (control 1–3), 3% CSE (1–3) or 10% CSE (1–3). RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representation of normalized signal intensity values for genes altered by ≥3.0-fold. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. (B) Table showing gene name, fold change and p-value for all genes upregulated by ≥3.0-fold. (C) Table showing gene name, fold change and p-value for all genes downregulated by ≥3.0-fold. Statistical significance (p<0.05) was calculated using student's t-test followed by Benjamini-Hochberg FDR correction on GeneSpring GX11.0.2 software. Fold change represents a comparison between mean normalised signal intensity for control (n = 3) versus smoke (n = 3) treated PBMCs. Refer to Data S2 for full data sets and Entrez Gene IDs.
Figure 7Expression of genes that were changed by 3.0-fold or above in PBMCs treated with control medium or cigarette smoke extract (CSE) for 24 hours.
PBMCs were treated for 24 hours with RPMI-1640 medium (control 1–3) or 3% CSE (1–3) or 10% CSE (1–3). RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representation of normalized signal intensity values for genes altered by ≥3.0-fold. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. (B) Table showing gene name, fold change and p-value for all genes upregulated by ≥3.0-fold. (C) Table showing gene name, fold change and p-value for all genes downregulated by ≥3.0-fold. Statistical significance (p<0.05) was calculated using student's t-test followed by Benjamini-Hochberg FDR correction on GeneSpring GX11.0.2 software. Fold change represents a comparison between mean normalised signal intensity for control (n = 3) versus smoke (n = 3) treated PBMCs. Refer to Data S2 for full data sets and Entrez Gene IDs.
Figure 8Expression of genes that were changed in both 3 and 10% cigarette smoke extract by 1.5 fold or above compared to control in PBMCs.
PBMCs were treated for 8 hours or 24 hours with RPMI-1640 medium (control 1–3), 3% CSE (1–3) or 10% CSE (1–3). RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representing normalized signal intensity values and list of genes altered by ≥1.5 fold in PBMCs treated with both 3 and 10% CSE after 8 hours. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. (B) Heat map representing normalized signal intensity values and list of genes altered by ≥1.5 fold in PBMCs treated with both 3 and 10% CSE after 24 hours. Red denotes high expression and turquoise denotes low expression. Order of samples was dictated by hierarchical clustering. Statistical significance (p<0.05) was calculated using one-way analysis of variants followed by a Tukey's post-hoc test and Benjamini-Hochberg FDR correction on GeneSpring GX11.0.2 software. Fold change represents a comparison between mean normalised signal intensity for control (n = 3) versus smoke (n = 3) treated PBMCs. Refer to Data S2 for full data sets and Entrez Gene IDs.
Figure 9Comparison of target gene expression in THP-1 cells and PBMCs treated with cigarette smoke extract (CSE).
We have previously shown that CSE increases the expression of HMOX1, TNF and IL8 in THP-1 cells and PBMCs. RNA was extracted from each sample and gene expression values measured using the Illumina HumanRef-8v3 BeadChip array. (A) Heat map representing normalized signal intensities of HMOX1, TNF and IL8 genes from THP-1 monocytes treated for 8 hours with RPMI-1640 (control 1–6) and 10% CSE (1–6). (B) Heat map representing normalized signal intensities of HMOX1, TNF and IL8 genes from PBMCs treated for 8 hours with RPMI-1640 (control 1–3), 3% and 10% CSE (1–3). (C) Heat map representing normalized signal intensities of HMOX1, TNF and IL8 genes from PBMCs treated for 24 hours with RPMI-1640 (control 1–3), 3% and 10% CSE (1–3). Heat maps were generated using GeneSpring GX11.0.2 software where, red denotes high expression and turquoise denotes low expression.
Top 5 networks in THP-1 cells after 8 h treatment with 10% CSE.
| Associated Network functions | Molecules in Network | Focus Molecules | Score |
|
| AKAP7, CDKN1A, CREB1, CRHR1, CYP1B1, EIF2S1, ERK1/2, FSH, HMOX1, Ifn gamma, IgG, IL5, IL8, IRF8, Jnk, LITAF, LPA, NFkB (complex), NINJ1, P2RY2, PIM1, PMAIP1, PPP1R15A, RNA polymerase II, RND3, SAT1, SERPINB2, SERPINB8, SERPINB10, SOAT1, SQSTM1, TDRD7, TNF, TNFAIP2, TNFAIP3 | 21 | 37 |
|
| ADRB2, ANXA1, BIK, CCL18, CTSC, CYSLTR1, DUSP5, DUSP10, G0S2, GBP1 (includes EG:2633), GCLM, GPR109B, IFNGR1, IL5, IL13, IRAK3, KRT15, LGALS3, LPL, LTB, MGST1, MMD, NID1, OSGIN1, RFTN1, RPS6KA2, RRM2, SLC3A2, SP1, SP3, TNF, TP53, TP53I3, TXNRD1, UBQLN2 | 11 | 15 |
|
| GABARAPL1, HDAC6 | 1 | 2 |
|
| NME1, SERTAD1 | 1 | 2 |
|
| MIR122 (includes EG:406906), SLC7A11 | 1 | 2 |
THP-1 monocytes were treated for 8 hours with RPMI-1640 control medium (n = 6) or 10% CSE-conditioned medium (n = 6). Genes that were significantly modified by ≥1.5-fold, as assessed using student's t-test followed by Benjamini-Hochberg FDR correction, were imported into Ingenuity Pathway Analysis software. The table shows the top 5 networks identified from genes differentially expressed by ≥1.5-fold in THP-1 monocytes treated with 10% CSE.
Top 5 networks in PBMCs after 8 h treatment with 10% CSE.
| Associated Network functions | Molecules in Network | Focus Molecules | Score |
|
| ACTB, Akt, ARHGEF6, BAG3, CD2, CRTC1, DNAJB1, DNAJB9, FKBP4, FSH, HBP1, HCFC1, Histone h4, Hsp70, Hsp90, HSPA8, IL2RB, IRS2, Lh, MAP1LC3B, MAPK6, MCM5, NQO1, OGT, p85 (pik3r), PGK1, PPP6R3, PRKCB, PSMD1, PTGES3, RAB2A, RBM39, STIP1, VCP, YWHAG | 27 | 35 |
|
| 26s Proteasome, ADRM1, ANXA1, Ap1, Caspase, CD19, CD46, CD81, CDKN1A, COMMD3, Creb,Cyclin E, DPYSL2, DUSP1, EP300, ERK, EWSR1, EZR, HMOX1, IFITM1, Jnk, KLHL21, MAP4K2, NFkB (complex), PDGF BB, PHLDA1, PRNP, PSMA3, PYCARD, RBL2, RELB, RGS1, TXN (includes EG:116484), TXNDC17, UBA7 | 26 | 33 |
|
| ADAM8, ADM, CD69, CXCR3, DUSP5, Hsp27, HSP90AB1, IFN Beta, Ifn gamma,IgG, IKBKE, IKK (complex), IL12 (complex), Interferon alpha, ITGAL, ITGB2, MYD88, P38 MAPK, PI3K (complex), PMAIP1, PPP1R15A, PSMB9, PSMB10, RGS2, SQSTM1, TAP1, TBK1, TCR, TICAM1, TIMP1, TNF, TNFSF10, TXNRD1, UGCG, ZC3HAV1 | 25 | 31 |
|
| CCNK, CDK9, DDX11/DDX12, DLEU1, E2F1, E2F6, EVL, FEN1, GCLM, GRN, HGF, HIST1H4A (includes others), HSPH1, ID2, ID3, MYC, MYOM2, NRIP1, PHB, PPP2R2A, PRDM5, PRDX1, RAD51, RBL2, SERTAD1, SHMT2, SKP2, SRXN1, SYTL1, TAGLN2, TFDP1, TIAM1, TOP2A, TOPBP1, UXT | 15 | 14 |
|
| ABCB6, AGT, AP1M1, BID, CALR, CANX, CAT, CD8A, CRKL, DOCK2, FXR1, HAGH, HCST, HLA-A,IFIT1, IFITM1, IFNG, IL7, KLRK1, KRT15, MHC Class I (complex), MXD1,Nfat (family), NLRC5, ODC1, PARVG, PELI1, PMAIP1, SAT1, SMARCA4, ST13, TNFRSF1B, TP73, WAS, WIPF1 | 15 | 14 |
PBMCs were treated for 8 hours with RPMI-1640 control medium (n = 3) or 10% CSE-conditioned medium (n = 3). Genes that were significantly modified by ≥1.5-fold, as assessed using student's t-test followed by Benjamini-Hochberg FDR correction, were imported into Ingenuity Pathway Analysis software. The table shows the top 5 networks identified from genes differentially expressed by ≥1.5-fold in PBMCs treated with 10% CSE.
Top 5 networks in PBMCs after 24 h treatment with 10% CSE.
| Associated Network functions | Molecules in Network | Focus Molecules | Score |
|
| ADA, ATF4, ATP1B3, BTG2, CCNC, CCNL1, CCT3, CCT6A, CDKN1A, DUSP1, ERK, FOXO1, GADD45A, GADD45G, GAPDH, GTF2B, HELZ, Histone h4, HSPB1, IgG, Jnk, KLHL21, MAP1LC3B, MAP4K2, PDGF BB, PPP1R15A, PSMA3, RB1CC1, RGS1, RNA polymerase II, RPL12, SLC38A2, TAF7, TAF10, TXN (includes EG:116484) | 29 | 34 |
|
| ABCC3, BCL11B, CD19, CD37, CD69, CD81, CYBA, CYBB, DNAJB4, EHD1, HLA-A, HLA-F, IFITM1,IFN Beta, Ifn gamma, IFNGR2,IL12 (complex), IL12 (family), IL7R, Immunoglobulin, Interferon alpha, IRF1, IRF8, MHC Class II (complex), MYD88, PMAIP1, PSMB8, PSMB9, SCO2, STAT1, STAT2, TAP1, TCR, TNF, XAF1 | 27 | 30 |
|
| ADM, Akt, DDIT3, DNAJB1, FCRLA, HLA-DMB, HMOX1, Hsp27, Hsp70, Hsp90, HSP90AB1, HSPA8,Igm, IL10,KDM3A, KEAP1, LDL, NAMPT, NCF1, NFE2L2, NFkB (complex), NQO1, P38 MAPK, PI3K (complex), Pkc(s), SQSTM1, STAT5A, STIP1, TAX1BP1, TBK1, TIMP1, TNFRSF25, TNFSF13B, UBA7, VCP | 25 | 27 |
|
| ACTB, APP, ARHGDIB, CBLB, CYTH1, CYTIP, DAPP1, DBNL, GABARAPL1, GRB2, HCST, HDAC6, ICAM3, ITGAL, ITGB2, LCP2, LDLRAP1, MAP3K5, MAP4K1, MARS, MFGE8, QARS, RAC2, SMARCA4, SMARCC1, SMARCE1, SNX27, SORL1, SPRY2, SUMO2, SYK, TRIP12, U2AF1, VAV, XPC | 18 | 16 |
|
| ACTN1, Ap1, CD55, CD97, CDC42EP4, CDK14, Creb, DNAJB9, E2f, ERK1/2, FSH, Histone h3, HSD3B2, KIDINS220, Lh, MAL, MAP1LC3B, MAPK6, MFAP1, MT2A, PGRMC1, PPAP2A, PSMD1, PTGER2, PTGS1, RAB4A, RASAL2, RGS12, SH3BP4, SH3GLB2, STK39, TFDP1, TLN1, TUBA1A, YTHDF2 | 15 | 14 |
PBMCs were treated for 24 hours with RPMI-1640 control medium (n = 3) or 10% CSE-conditioned medium (n = 3). Genes that were significantly modified by ≥1.5-fold, as assessed using student's t-test followed by Benjamini-Hochberg FDR correction, were imported into Ingenuity Pathway Analysis software. The table shows the top 5 networks identified from genes differentially expressed by ≥1.5-fold in PBMCs treated with 10% CSE.
Top canonical pathways in THP-1 cells after 8 h treatment with 10% CSE.
| Canonical Pathways | Molecules in Network | p-value | Ratio |
|
| HMOX1, MGST1, NQO2, NQO1, SQSTM1, GCLM, TXNRD1, MAFG | 1.39×10−5 | 8/188 (0.043) |
|
| MGST1, NQO2, NQO1, CDKN1 A, TNF, CYP1B1 | 2.21×10−4 | 6/141 (0.043) |
|
| HMOX1, MGST1, NQO2, NQO1, CHST12, TNF, CYP1B1, CITED2 | 2.28×10−4 | 8/265 (0.03) |
|
| IL8, HSPA1B, ANXA1, CREB1, CDKN1A, TNF, ADRB2 | 1.01×10−3 | 7/278 (0.025) |
|
| IL8, TNF | 1.19×10−3 | 2/8 (0.25) |
THP-1 cells were treated for 8 hours with RPMI-1640 control medium (n = 6) or 10% CSE-conditioned medium (n = 6). Genes that were significantly modified by ≥1.5-fold, as assessed using student's t-test followed by Benjamini-Hochberg FDR correction, were imported into Ingenuity Pathway Analysis software. The table shows the top 5 canonical pathways identified from genes differentially expressed by ≥1.5-fold in THP-1 cells treated with 10% CSE. The P-value for association of genes and the described canonical pathways, and the ratio of significantly differentially expressed pathway components compared to the total components in that pathway was generated using Fisher's exact test.
Figure 10Top 5 canonical pathway gene interactions in THP-1 cells treated cigarettes smoke extract for 8 hours.
The top 5 canonical pathways identified from genes differentially expressed by ≥1.5-fold in THP-1 cells treated with 10% CSE. RNA was extracted from each sample and gene expression levels were measured using the Illumina HumanRef8-v3 BeadChip Array.Genes that were significantly modified by ≥1.5-fold according to the student's t-test and Benjamini-Hochberg FDR correction were imported into Ingenuity Pathway Analysis software. Interactions of these genes are represented in this schematic.
Top canonical pathways in PBMCs after 8 h treatment with 10% CSE.
| Canonical Pathways | Molecules in network | p-value | Ratio |
|
| AKR7A2, UBB, SOD1, ACTB, NQO1, DNAJA4, DNAJA1, DNAJB9, ACTG1, TXNRD1, EP300, HMOX1, STIP1, VCP, PIK3R2, SQSTM1, DNAJB6, DNAJB1, TXN (includes EG:116484), GCLM, GSTK1, PRKCB | 4.90×10−12 | 22/188 (0.117) |
|
| PSMB9, UBB, PSMA3, UBE2A, HSPA1A/HSPA1B, PSMB10, HSPH1, DNAJB9, DNAJA1, PSMB6, TAP1, TCEB1, HSPA8, HSP90AB1, HSP90AA1, PSMD1, DNAJB6, DNAJB1, UBC | 8.02×10−7 | 19/269 (0.071) |
|
| HSPA8, HSP90AB1, HSPA1A/HSPA1B, DUSP1, HSPH1, HSP90AA1, PIK3R2, DNAJB6, DNAJB1, DNAJB9, DNAJA1, PRKCB | 4.17×10−5 | 12/157 (0.076) |
|
| HSPA1A/HSPA1B, IKBKE, CD3D, EP300, HSPA8, HSP90AB1, VIPR1, DUSP1, ANXA1, CDKN1A, FKBP4, PTGES3, HSP90AA1, PIK3R2, TNF | 1.70×10−4 | 15/278 (0.054) |
|
| HLA-E, CD69, ACTB, TNFSF10, TNF, ACTG1, IL2RB, ITGAL | 3.33×10−4 | 8/91 (0.088) |
PBMCs were treated for 8 hours with RPMI-1640 control medium (n = 6) or 10% CSE-conditioned medium (n = 6). Genes that were significantly modified by ≥1.5-fold, as assessed, using student's t-test followed by Benjamini-Hochberg FDR correction were imported into Ingenuity Pathway Analysis software. The table shows the top 5 canonical pathways identified from genes differentially expressed by ≥1.5-fold in PBMCs treated with 10% CSE. The P-value for association of genes and the described canonical pathways, and the ratio of significantly differentially expressed pathway components compared to the total components in that pathway was generated using Fisher's exact test.
Figure 11Top 5 canonical pathway gene interactions in PBMCstreated with 10% CSE for 8 hours.
The top 5 canonical pathways identified from genes differentially expressed by ≥1.5-fold in PBMCs treated with 10% CSE. RNA was extracted from each sample and gene expression levels were measured using the Illumina HumanRef8-v3 BeadChip Array.Genes that were significantly modified by ≥1.5-fold as assessed using student's t-test followed by Benjamini-Hochberg FDR correction were imported into Ingenuity Pathway Analysis software. Interactions of these genes are represented in the schematic as determined by experimentation in human cells.
Top canonical pathways in PBMCs after 24 h treatment with 10% CSE.
| Canonical Pathways | Molecules in Network | p-value | Ratio |
|
| USP14, PSMA3, PSMD7, DNAJB4, HSPA1A/HSPA1B, UBR2, PSMB8, DNAJA1, TCEB1, TAP1, PSMB6, UBE2F, HSP90AB1, HLA-A, PSMD14, DNAJB1, PSMC2, PSMB4, PSMB9, UBB, PSMB5, HSPH1, USP38, HSPA9, PSMC4, PSMD6, PSMA1, DNAJB9, UBE2L6, PSMD8, HSPA8, PSMB7, PSMC1, HSCB, PSMB2, PSMD2, PSMD12, PSMA4, PSMD1, DNAJB6, PSMC3, DNAJC7, HSPB1 | 3.13×10−20 | 43/269 (0.160) |
|
| AKR7A2, USP14, PRDX1, DNAJB4, NQO2, DNAJA4, DNAJA1, MAFG, HMOX1, KEAP1, VCP, ATF4, GCLM, TXN (includes EG:116484), DNAJB1, PIK3R2, NFE2L2, GSTK1, UBB, SOD1, NQO1, HERPUD1, DNAJB9, ACTG1, TXNRD1, ERP29, STIP1, DNAJB6, SQSTM1, DNAJC7, PRKCB | 1.60×10−14 | 31/188 (0.165) |
|
| PSMB9, HLA-DMA, PSMB5, HLA-A, HLA-DOB, HLA-DMB, PSMB8, TAP1, PSMB6, HLA-DPA1, HLA-F | 1.62×10−7 | 11/43 (0.256) |
|
| IFNGR2, IFITM1, MX1, IFI35, STAT2, PSMB8, STAT1, TAP1, IRF1 | 4.82×10−8 | 9/34(0.265) |
|
| PLCB2, DNAJB4, HSPA1A/HSPA1B, HSPH1, HSPA9, DNAJB9, DNAJA1, HSPA8, HSP90AB1, HSCB, DUSP1, DNAJB6, DNAJB1, PIK3R2, DNAJC7, PRKCB, HSPB1 | 3.09×10−6 | 17/157 (0.108) |
PBMCs were treated for 24 hours with RPMI-1640 control medium (n = 6) or 10% CSE-conditioned medium (n = 6). Genes that were significantly modified by ≥1.5-fold, as assessed, using student's t-test followed by Benjamini-Hochberg FDR correction were imported into Ingenuity Pathway Analysis software. The table shows the top 5 canonical pathways identified from genes differentially expressed by ≥1.5-fold in PBMCs treated with 10% CSE. The P-value for association of genes and the described canonical pathways, and the ratio of significantly differentially expressed pathway components compared to the total components in that pathway was generated using Fisher's exact test.
Figure 12Top 5 canonical pathway gene interactions in PBMCs treated with 10% CSE for 24 hours.
The top 5 canonical pathways identified from genes differentially expressed by ≥1.5-fold in PBMCs treated with 10% CSE. RNA was extracted from each sample and gene expression levels were measured using the Illumina HumanRef8-v3 BeadChip Array and genes that were modified by ≥1.5-fold and significantly changed according to student's t-test followed by Benjamini-Hochberg FDR correction were imported into Ingenuity Pathway Analysis software. Interactions of these genes are represented in the figure.
Genes observed to be differentially expressed by ≥2-fold in THP-1 monocytes in response to cigarette smoke were also differentially expressed in previous studies examining the effects of cigarette smoke on various cell types in vivo and in vitro.
| Symbol | Entrez ID | Reg | FC | Description | Reference |
|
| 3162 | up | 22.6 | heme oxygenase 1 |
|
|
| 9242 | up | 5.8 | musculin (activated B-cell factor-1) | |
|
| 2730 | up | 4.8 | glutamate-cysteine ligase, modifier subunit |
|
|
| 1728 | up | 3.8 | NAD(P)H quinone oxioreductase 1 |
|
|
| 6016 | up | 3.1 | Ras-like without CAAX 1 | |
|
| 140809 | up | 2.3 | sulfiredoxin 1 |
|
|
| 1545 | up | 2.3 | cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
|
| 2504 | up | 2.9 | ferritin, heavy polypeptide-like 12 | |
|
| 4199 | up | 3.4 | NADP(+)-dependent malic enzyme 1 |
|
|
| 56666 | up | 2.7 | pannexin 2 | |
|
| 84803 | up | 2.5 | Glycerol -3-phosphate acetyltransferase 9 |
|
|
| 3576 | up | 2.7 | interleukin 8 |
|
|
| 55652 | up | 2.7 | Solute carrier family 48 (heme transporter), member 1 | |
|
| 2500 | up | 2.5 | ferritin, heavy polypeptide-like 7 | |
|
| 7296 | up | 2.6 | thioredoxin reductase 1 (transcript variant 1) |
|
|
| 23657 | up | 2.0 | solute carrier family 7 |
|
|
| 8544 | up | 2.7 | pirin (transcript variant 2) |
|
|
| 65259 | up | 2.4 | chromosome 16 open reading frame 28 mRNA | |
|
| 2498 | up | 2.0 | ferritin, heavy polypeptide-like 3 | |
|
| 8878 | up | 2.5 | sequestosome 1 | |
|
| 7296 | up | 2.3 | thioredoxin reductase 1 (transcript variant 4) |
|
|
| 23710 | up | 2.7 | GABA(A) receptor-associated protein like 1 |
|
|
| 8544 | up | 2.7 | pirin (transcript variant 1) |
|
|
| 7124 | up | 2.1 | tumor necrosis factor |
|
|
| 5226 | up | 2.5 | phosphogluconate dehydrogenas |
|
|
| 5055 | down/up | 3.8 | Plasminogen activator inhibitor |
|
|
| 2841 | down | 2.2 | N-arachidonyl glycine receptor | |
|
| 389816 | down | 2.3 | Leucine-rich repeat-containing protein 26 | |
|
| 389816 | down | 2.2 | Leucine-rich repeat-containing protein 26 |
Observed in airway epithelial cells,
Observed in lung tissue,
Observed in monocytes,
Observed in macrophages,
Observed in oral leukoplakia,
Observed in peripheral blood mononuclear cells (PBMCs),
Observed in bronchioalveolar lavage (BAL), The symbol LOC3898186* is a predicted cDNA sequence similar to LOC3898186.